Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) immunotherapy
Open Access
- 1 March 1995
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 99 (3) , 369-375
- https://doi.org/10.1111/j.1365-2249.1995.tb05560.x
Abstract
Intravesical immunotherapy for carcinoma in situ of the bladder is arguably the most effective form of tumour immunotherapy described to date. Following repeated instillations of BCG organisms into the bladder, large quantities of cytokines are detected in patients’ urine. This study concerns the production of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and soluble ICAM-1 (sICAM-1) throughout the six weekly instillations which comprise a therapeutic course. Sequential instillations of BCG induced secretion of IL-1β, IL-2, IL-6, IL-8, IL-10, TNF-α, IFN-γ and sICAM-1 into urine. The responses were heterogeneous between patients and cytokines, but some general trends were evident. Although cytokine levels were initially low, their concentration increased with repeated instillation of BCG. Certain cytokines (e.g. IL-6, IL-8 and IL-10) could be detected after the first instillation, whilst others (e.g. IL-2 and IFN-γ) were not detected until after the third or fourth instillation. Interestingly, IL-4 was not detected, perhaps suggesting a differential effect on Th2-like responses. Some patients produced particularly elevated or non-detectable levels of cytokines, and a positive correlation was found between the production of various cytokines. The production of a particular cytokine did not correspond with lack of production of another species. Whether monitoring the production of cytokines following therapy may be of prognostic value will be determined in a larger series of patients. However, as these potent immunomodulators are thought t o be important for the 75% complete clinical response observed with BCG therapy, there remains the possibility that detection of the products of an activated immune system may correlate with eventual clinical outcome. This study is a necessary forerunner to full prognostic evaluation of such immunological data.Keywords
This publication has 31 references indexed in Scilit:
- Autocrine regulation of ICAM-1 expression on bladder cancer cell lines: evidence for the role of IL-1αImmunology Letters, 1994
- Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.Journal of Clinical Pathology, 1994
- Growth inhibition of Mycobacterium bovis by IFN-γ stimulated macrophages: regulation by endogenous tumor necrosis factor-α and by IL-10International Immunology, 1994
- A DUAL MECHANISM OF IMMUNOSUPPRESSION BY FK-506 DIFFERENTIAL SUPPRESSION OF IL-4 AND IL-10 LEVELS IN T HELPER 2 CELLSTransplantation, 1993
- The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapyCancer Immunology, Immunotherapy, 1993
- Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancerCancer Immunology, Immunotherapy, 1992
- Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-GuérinCancer Immunology, Immunotherapy, 1990
- HLA—DR Expression by High Grade Superficial Bladder Cancer Treated with BCGBritish Journal of Urology, 1989
- Local Immune Responses after Intravesical BCG Treatment for Carcinoma in situBritish Journal of Urology, 1987
- Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancerClinical Immunology and Immunopathology, 1986